Tiziana Life Sciences PLC's (LON:TILS) (NASDAQ:TLSA) Gabriele Cerrone chats to Proactive London's Andrew Scott following the news they're looking to expedite development of a drug it believes could help coronavirus patients with severe lung damage.
The company’s TZLS-501 is a class of monoclonal antibody (mAb) called an anti-interleukin-6 receptor and recent testing has revealed they have a significant role to play in treating coronavirus patients.